WC2022 Programme Overview

(updated at 8 June 2022)
Programme is subject to change without prior notice.

How will Varian and Siemens Healthineers work together to pioneer new breakthroughs in oncology?
Details Date: 14 June 2022
Time: 1230 – 1330hrs
Kenneth Tan, President at Varian APJI

Kenneth Tan is the SVP & President of Asia Pacific, Japan and India at Varian. He has 20 years of experience in healthcare; having held strategy and commercial leadership roles managing businesses of more than half a billion in Varian, Medtronic, Covidien, Boston Scientific and Novartis.

More than 15 years are in the implantable, disposable medical devices, capital equipment and managed services; covering various Global markets and regions in Asia Pacific. He has deep experience in developing and executing product commercialisation and strategic growth plans in China, Japan, India, and South-East Asia.

Kenneth has built his success around driving complex strategic shifts through organisations; in areas of business strategy and organisational transformation. The hallmarks of his tenure are growth acceleration, business-model innovation and a strong leadership team.

In the area of leadership development, Kenneth is passionate about “Fair-Process Leadership” and driving Diversity, Equity and Inclusion. He firmly believes that Purpose, Culture and Sustainability are key strategic pillars for organisations to thrive and attract a new generation of leaders.

Kenneth’s academic foundation is in Biotechnology, and he obtained his BBA from the University of South Australia. He is an alumnus of INSEAD, having completed their Advanced Management Program.

Dr Jeremy Booth, Director, Radiation Oncology Medical Physics – Northern Sydney Cancer Centre, Royal North Shore Hospital Sydney

Dr Jeremy Booth is Director of Medical Physics at Northern Sydney Cancer Centre (NSCC) at Royal North Shore Hospital (RNSH) and Adjunct Senior Lecturer at School of Physics University of Sydney. Jeremy completed his doctoral study on methods to account for prostate motion in radiotherapy in 2002 and completed his clinical certification in 2005. By 2007, he was Deputy Director of Medical Physics and then Director from 2010. Jeremy leads a team of 14 clinical scientists to support a Radiation Oncology clinical, development and research agenda. Jeremy has significant experience in implementing advanced radiotherapy techniques as evidenced by RNSH leading New South Wales in the largest proportion of dynamic IMRT and VMAT treatments and the most mature SABR/SBRT program.

Jeremy Booth has a strong record of clinical translation and collaboration in radiotherapy physics. Dr Booth has made a significant contribution to the field of medical physics; specifically with research and development in real-time adaptive radiotherapy. Dr Booth has accrued over $7.5M in research grants from government and industry to develop and lead 5 world-first medical device clinical trials to improve treatment for prostate, breast and lung cancer patients. Jeremy has authored over 70 manuscripts and is regularly invited to present at International conferences. More recently, Dr Booth is the lead investigator for a novel adaptive radiotherapy industry venture that will provide new level of accuracy and automation as a paradigm shift for radiotherapy. Dr Booth is an opinion leader, who has contributed to national guidelines for radiotherapy centre design for NSW Health, international guidelines for MLC tracking for American Association of Physicists in Medicine and national guidelines for the safe implementation of stereotactic body radiotherapy.

Northern Sydney Cancer Centre at RNSH has an excellent reputation for being early adopters of technology; providing sophisticated treatment techniques, and excellent patient outcomes. Jeremy’s team has forged strong links with Prof Paul Keall at University of Sydney and Varian Medical Systems. Jeremy collaborates actively to bring world class support to technology implemented at Northern Sydney Cancer Centre with the University of Newcastle for WATCHDOG and SPARK studies, the University of Wollongong for radiation detector research, the University of Michigan within an international QA consortium and Aarhus University regarding our core KIM and MLC tracking research. Jeremy is an expert in real-time adaptive radiotherapy and participates in the Varian Adaptive Intelligence Consortium.


How will Varian and Siemens Healthineers work together to pioneer new breakthroughs in oncology? Kenneth Tan, President at Varian APJI, discusses how the unique capabilities of each company will combine to drive the next transformation in healthcare - from personalised diagnosis and planning, to intelligent and image guided treatment.

Followed by Dr Jeremy Booth, Director, Radiation Oncology Medical Physics – Northern Sydney Cancer Centre, Royal North Shore Hospital Sydney

Adaptive Radiotherapy: Insights for Ethos clinical implementation.